{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:40:06Z","timestamp":1773290406325,"version":"3.50.1"},"reference-count":22,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5,1]]},"abstract":"<jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>FSH and anti-M\u00fcllerian hormone (AMH) are, individually, widely used to assess functional ovarian reserve (FOR) but demonstrate discrepancies in efficacy. How predictive they are combined is unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>The purpose of this study was to assess predictive values of different FSH and AMH combinations on in vitro fertilization (IVF).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design and Setting:<\/jats:title>\n                  <jats:p>FSH and AMH levels in patients were categorized as low, normal, and high, based on age-specific 95% confidence intervals. This allowed for establishment of nine combinations of low, normal, or high FSH\/AMH patient categories. With use of various statistical methods, patients in individual categories were then compared in outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients:<\/jats:title>\n                  <jats:p>We investigated 544 consecutive infertility patients in their first IVF cycles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions:<\/jats:title>\n                  <jats:p>IVF cycles were managed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures:<\/jats:title>\n                  <jats:p>Oocyte yields and implantation and pregnancy rates, adjusted for age and fragile X mental retardation 1 (FMR1) genotypes\/subgenotypes, were measured.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>The most notable repeated finding was a strong statistical association of the FSH\/AMH high\/high category (characterized by abnormally high FSH and AMH levels) with favorable IVF outcomes compared with outcomes for other FSH\/AMH variations (4.34 times odds of high oocyte yields and 1.93 times odds of clinical pregnancy). Addition of age to the model only minimally further improved the odds of pregnancy to 2.03 times. The positive association with high oocyte yields, however, turned negative (0.75 times lower yields) with addition of FMR1 to the model for women with FSH\/AMH high\/high and the het-norm\/low FMR1 subgenotype compared with women with the norm FMR1 genotype and other FSH\/AMH categories.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>In the absence of het-norm\/low FMR1, abnormally high FSH and AMH, a seemingly contradictory combination, reflects highly beneficial outcomes in IVF compared with the other FSH\/AMH categories, suggesting greater importance of FSH in early follicle maturation than currently recognized. The study also confirms adverse outcome effects of het-norm\/low FMR1 and, therefore, the gene's importance for reproductive success.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2013-1051","type":"journal-article","created":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T05:09:05Z","timestamp":1364360945000},"page":"2136-2145","source":"Crossref","is-referenced-by-count":15,"title":["Clinical Relevance of Combined FSH and AMH Observations in Infertile Women"],"prefix":"10.1210","volume":"98","author":[{"given":"Norbert","family":"Gleicher","sequence":"first","affiliation":[{"name":"Foundation for Reproductive Medicine (N.G., D.H.B.), New York, New York 10021"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Kim","sequence":"first","affiliation":[{"name":"The Center for Human Reproduction (N.G., A.K., V.K., A.W., A.S.-T., E.L., H.-J.L., D.H.B.) New York, New York 10021"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitaly","family":"Kushnir","sequence":"first","affiliation":[{"name":"The Center for Human Reproduction (N.G., A.K., V.K., A.W., A.S.-T., E.L., H.-J.L., D.H.B.) New York, New York 10021"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Weghofer","sequence":"first","affiliation":[{"name":"The Center for Human Reproduction (N.G., A.K., V.K., A.W., A.S.-T., E.L., H.-J.L., D.H.B.) New York, New York 10021"},{"name":"Department of Gynecologic Endocrinology and Reproductive Medicine (A.W.), Medical University Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Shohat-Tal","sequence":"first","affiliation":[{"name":"The Center for Human Reproduction (N.G., A.K., V.K., A.W., A.S.-T., E.L., H.-J.L., D.H.B.) New York, New York 10021"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Lazzaroni","sequence":"first","affiliation":[{"name":"The Center for Human Reproduction (N.G., A.K., V.K., A.W., A.S.-T., E.L., H.-J.L., D.H.B.) New York, New York 10021"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Joon","family":"Lee","sequence":"first","affiliation":[{"name":"The Center for Human Reproduction (N.G., A.K., V.K., A.W., A.S.-T., E.L., H.-J.L., D.H.B.) New York, New York 10021"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Barad","sequence":"first","affiliation":[{"name":"Foundation for Reproductive Medicine (N.G., D.H.B.), New York, New York 10021"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071613092362100_B1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1477-7827-9-23","article-title":"Defining ovarian reserve to better understand ovarian aging","volume":"9","author":"Gleicher","year":"2011","journal-title":"Reprod Biol Endocrinol"},{"key":"2020071613092362100_B2","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1210\/jc.2010-0701","article-title":"Clinical utility of measurement of anti-M\u00fcllerian hormone in reproductive endocrinology","volume":"95","author":"Ledger","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613092362100_B3","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.fertnstert.2008.03.034","article-title":"Correlation of antimullerian hormone and baseline follicle-stimulating hormone levels","volume":"91","author":"Singer","year":"2009","journal-title":"Fertil Steril"},{"key":"2020071613092362100_B4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1472-6483(10)60287-8","article-title":"Relevance of basal serum FSH to IVF outcome varies with patient age","volume":"17","author":"Sabatini","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"2020071613092362100_B5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1477-7827-8-64","article-title":"Discordance between follicle stimulating hormone (FSH) and anti-M\u00fcllerian hormone (AMH) in female infertility","volume":"8","author":"Gleicher","year":"2010","journal-title":"Reprod Biol Endocrinol"},{"key":"2020071613092362100_B6","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.fertnstert.2008.09.069","article-title":"Comparing anti-M\u00fcllerian hormone (AMH) and follicle- stimulating hormone (FSH) as predictors of ovarian function","author":"Barad","year":"2009","journal-title":"Fertil Steril"},{"key":"2020071613092362100_B7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.fertnstert.2011.04.003","article-title":"Antim\u00fcllerian hormone and polycystic ovary syndrome","volume":"96","author":"Lin","year":"2011","journal-title":"Fertil Steril"},{"key":"2020071613092362100_B8","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S1472-6483(10)60037-5","article-title":"Polycystic ovary syndrome, body mass index and outcome of assisted reproductive technologies","volume":"18","author":"Beydoun","year":"2009","journal-title":"Reprod Biomed Online"},{"key":"2020071613092362100_B9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/01.AOG.0000264065.37661.a0","article-title":"Age-specific levels of basal follicle-stimulating hormone assessment of ovarian function","volume":"109","author":"Barad","year":"2007","journal-title":"Obstet Gynecol"},{"key":"2020071613092362100_B10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.rbmo.2010.12.002","article-title":"Utility of age-specific serum anti-M\u00fcllerian hormone concentrations","volume":"22","author":"Barad","year":"2011","journal-title":"Reprod Biomed Online"},{"key":"2020071613092362100_B11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2006.09.004","article-title":"The FMR1 premutation and reproduction","volume":"87","author":"Wittenberger","year":"2007","journal-title":"Fertil Steril"},{"key":"2020071613092362100_B12","doi-asserted-by":"crossref","first-page":"e15303","DOI":"10.1371\/journal.pone.0015303","article-title":"FMR1 genotype with autoimmunity-associated polycystic ovary-like phenotype and decreased pregnancy chance","volume":"5","author":"Gleicher","year":"2010","journal-title":"PLoS ONE"},{"key":"2020071613092362100_B13","doi-asserted-by":"crossref","first-page":"e18781","DOI":"10.1371\/journal.pone.0018781","article-title":"Association of FMR1 genotypes with in vitro fertilization (IVF) outcomes based on ethnicity\/race","volume":"6","author":"Gleicher","year":"2011","journal-title":"PLoS ONE"},{"key":"2020071613092362100_B14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1369\/0022155412441002","article-title":"Ovarian abnormalities in a mouse model of fragile X primary ovarian insufficiency","volume":"60","author":"Hoffman","year":"2012","journal-title":"J Histochem Cytochem"},{"key":"2020071613092362100_B15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.fertnstert.2012.09.038","article-title":"Criteria for number of embryos to transfer: a committee opinion","volume":"99","author":"Practice Committee of the American Society for Reproductive Medicine and Practice Committee of the American Society for Assisted Reproductive Technology","year":"2013","journal-title":"Fertil Steril"},{"key":"2020071613092362100_B16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1477-7827-9-67","article-title":"Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR)","volume":"9","author":"Gleicher","year":"2011","journal-title":"Reprod Biol Endocrinol"},{"key":"2020071613092362100_B17","article-title":"Diminished functional ovarian reserve (DOR) is at all ages characterized by androgen deficiency, responsive to androgen supplementation","author":"Gleicher","year":"2012","journal-title":"J Assist Reprod Genet"},{"key":"2020071613092362100_B18","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/humrep\/der479","article-title":"Antral follicle responsiveness to follicle-stimulating hormone administration assessed by the Follicular Output RaTe (FORT) may predict in vitro fertilization-embryo transfer outcome","volume":"27","author":"Gallot","year":"2012","journal-title":"Hum Reprod"},{"key":"2020071613092362100_B19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1210\/jc.2011-2403","article-title":"Towards a better understanding of functional ovarian reserve: AMH (AMHo) and FSH (FSHo) hormone ratios per retrieved oocyte","volume":"97","author":"Gleicher","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613092362100_B20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.fertnstert.2012.06.017","article-title":"Does the level of serum antim\u00fcllerian hormone predict ovulatory function in women with polycystic ovary syndrome with aging?","volume":"98","author":"Carmina","year":"2012","journal-title":"Fertil Steril"},{"key":"2020071613092362100_B21","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/humrep\/des213","article-title":"Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?","volume":"27","author":"Eilertsen","year":"2012","journal-title":"Hum Reprod"},{"key":"2020071613092362100_B22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/humrep\/den363","article-title":"Ovarian function: a theory of relativity","volume":"24","author":"Weghofer","year":"2009","journal-title":"Hum Reprod"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/5\/2136\/9048465\/jcem2136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/5\/2136\/9048465\/jcem2136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:09:26Z","timestamp":1594940966000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/98\/5\/2136\/2537101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,1]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2013-1051","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,1]]}}}